Systematic review and meta-analysis examining the relationship between postprandial hypotension, cardiovascular events, and all-cause mortality

David JA Jenkins,1,2,3,4,5 Sandhya Sahye-Pudaruth,1,4 Khosrow Khodabandeuhlou,6 Fred Liang,7 Maaria Kasmani,8 Jessica Wanyan,9 Maggie Wang,10 Keishini Selvaganesh,10 Melanie Paquette,1,4 Darshna Patel,1,4 Andrea J Glenn,1,3,4 Korbua Srichaikul,1,4 Cyril WC Kendall,1,3,4,11 and John L Sievenpiper1,2,3,4,5

1Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; 2Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, Ontario, Canada; 3Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Toronto, Ontario, Canada; 4Clinical Nutrition Risk Factor Modification Centre, St. Michael’s Hospital, Toronto, Ontario, Canada; 5Division of Endocrinology and Metabolism, St. Michael’s Hospital, Toronto, Ontario, Canada; 6Faculty of Science, York University, Toronto, Ontario, Canada; 7Department of Physiology and Immunology, University of Toronto, Toronto, Ontario; 8School of Medicine, University College of Dublin, Dublin, Ireland; 9Department of Human Biology, University of Toronto, Toronto, Ontario; 10Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada; and 11College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

ABSTRACT

Background: Postprandial hypotension (PPH) has been reported to be associated with syncope, falls, adverse cardiovascular outcomes, and increased all-cause mortality. It has been reported to have an incidence as high as 30% in the elderly and persons with diabetes. We therefore performed a meta-analysis to determine the relation of PPH with cardiovascular disease (CVD) events and all-cause mortality.

Objectives: Our objective was to conduct a systematic review and meta-analysis of cohort and cross-sectional studies to determine the association of PPH with CVD and all-cause mortality.

Methods: We searched the databases MEDLINE, EMBASE, and Cochrane library up to 13 April 2022 for prospective cohort and cross-sectional studies that examined the association of PPH with CVD outcomes and all-cause mortality. Data were analyzed using the generic inverse variance method with a random-effects model. Grading of Recommendations, Assessment, Development, and Evaluation approach assessed the certainty of evidence.

Results: Seven studies that included 2389 participants met our inclusion criteria. PPH was associated with each outcome individually, including increased all-cause mortality, total CVD, CVD mortality, and stroke. CVD outcomes and all-cause mortality combined were also associated with PPH (RR: 1.52; 95% CI: 1.05, 2.18; P = 0.03; I² = 77%). The certainty of evidence was graded as very low due to significant heterogeneity and the limited number of studies.

Conclusions: This assessment indicates an association of PPH with CVD and all-cause mortality. Further studies are required to improve CVD and mortality estimates, but the potential seriousness of CVD and all-cause mortality as outcomes of PPH justifies more screening, diagnosis, and research.

Keywords: postprandial hypotension, cardiovascular disease, all-cause mortality, stroke, meta-analysis

Introduction

Postprandial hypotension (PPH) is a well-documented phenomenon but has received little attention clinically as a cause of concern. The disorder appears to be more common with increasing age, diabetes, and autonomic neuropathy (1, 2). It has been associated with syncope and falls (3) and also with cardiovascular events and increased all-cause mortality (4). The incidence has been reported to be on the order of 10–30% of the residents of long-term care homes (4–7). PPH has been defined as a postmeal reduction in systolic blood pressure of >20 mmHg during the first 2 h after the start of a meal (8). It is most commonly seen after the first meal of the day and is thought to be due to the increased mesenteric blood flow to supply the gut, possibly compounded by insulin-induced peripheral vasodilation.
vasodilatation (9–14). This “steal” of blood from the systemic circulation results in a potential fall in systemic blood pressure and a compensatory increase in pulse rate and cardiac output to maintain systemic blood pressure in healthy people. This process is deficient in those who have PPH (9, 15).

PPH appears treatable through lifestyle change by increasing the meal fluid volume, reducing meal content of carbohydrates, and possibly altering the physiologic effect of the carbohydrate pharmacologically by reducing the rate of carbohydrate digestion (12, 16) and gastric emptying (17–19).

The attention paid to PPH as a possible cause of cardiovascular disease (CVD) and all-cause mortality has been based on a relatively few small studies (4, 8, 12, 20–22). However, because of the potential seriousness of these outcomes, we felt it important to undertake a systematic review and meta-analysis to determine the consistency of the data. We have focused on cohort and cross-sectional studies that explored the association of PPH with CVD and all-cause mortality among older community-dwelling and long-term care facility residents. We hypothesized that PPH may be associated with increased CVD and all-cause mortality outcomes. Demonstration of these associations will encourage further research in this area, routine screening, and treatment to reduce adverse events in the future.

Methods

Design

We followed the Cochrane Handbook for Systematic Reviews and Interventions (23) and reported the results according to Meta-analysis of Observational Studies in Epidemiology (24) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The study protocol is registered at https://www.crd.york.ac.uk/PROSPERO/ (PROSPERO identifier, CRD42021262425).

Study selection

We conducted a literature search in Cochrane Library, MEDLINE, and EMBASE up to 13 April 2022 using the search terms “postprandial hypotension” AND (“cardiovascular disease” OR “stroke” OR “myocardial infarction” OR “syncope” OR “heart failure” OR “all-cause mortality”) that was supplemented by a manual search (see Supplemental Table 1 for our full search terms). The search was restricted to human studies without any restrictions on publication date and language. We included prospective, retrospective, cross-sectional, and case-control studies conducted in adult human populations examining the relation between PPH and CVD, CVD mortality, heart failure, stroke, myocardial infarction (MI), syncope, and all-cause mortality, with prospective cohorts followed for ≥6 mo. Excluded were studies conducted in the laboratory and those done with animals, children, pregnant and breastfeeding women, and those with chronic infections (e.g., HIV and hepatitis C).

Data extraction

Full-article review and data extraction were conducted twice by independent reviewers (KK, FL, MK, KSelvaganesh, JW, or MW) with all disagreements reconciled through consensus. Attempts were also made to contact the authors where needed. As with all meta-analyses, the outcomes tend to be exploratory in nature with total CVD, CVD mortality, and all-cause mortality being the outcomes of primary interest and the secondary outcomes of interest being the components of CVD (stroke and MI).

Risk of bias assessment

The quality of the prospective cohort studies included in the meta-analysis was assessed by the Newcastle–Ottawa Scale (NOS) (25). A maximum of 9 points can be given based on cohort selection, comparability of cohorts, and ascertainment of outcome, and studies scoring ≥6 points were considered high-quality studies. The Joanna Briggs Institute (JBI) appraisal checklist for analytical cross-sectional studies was used to assess the quality of the included cross-sectional studies. The overall ratings were “Include,” “Exclude,” and “Seek further information” (26).

Outcomes

The outcomes were exploratory, with the primary interests being most adjusted RRs for total CVD, CVD mortality, and all-cause mortality and secondary interests being CVD-related outcomes (please see “Data extraction” above).

Data synthesis

Data were analyzed using Review Manager (RevMan) version 5.4 (The Nordic Cochrane Centre, The Cochrane Collaboration) and STATA software version 16.1 (StataCorp) with between-study variability estimated by τ² (DerSimonian-Laird). Pooled analyses were conducted using the generic inverse variance method with random-effects models. Data were expressed as RRs with 95% CIs. Heterogeneity between the studies was assessed through the Cochrane Q statistic at P < 0.1 and quantified by I². We interpreted I² ≥ 50% as substantial heterogeneity with P < 0.1 (27). If 10 or more studies were detected, publication bias was assessed by visual inspection of the funnel plots and using the Begg and Egger tests, where P < 0.05 was considered evidence of small study effects (28, 29).

Grading of the evidence

The overall certainty of evidence of all studies was assessed using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) (30, 31). By default, prospective cohort studies are graded as low-certainty evidence. Criteria to downgrade included study limitations (as assessed by the NOS), inconsistency (substantial or unexplained interstudy heterogeneity, I² > 50% and P < 0.10), indirectness (presence of factors that limit the generalizability of the results), imprecision [the 95% CI for effect estimates crosses a minimally important difference of 5% (RR: 0.95–1.05) from the line of unity], and publication bias (significant evidence of small study effects).
Results

Flow of the literature

We identified a total of 7 studies [5 cohorts identified from our comprehensive search (6, 20, 21, 32, 33) and 2 cross-sectional studies identified from our manual search (3, 22)] that included a total of 2389 participants, out of which 3 studies were included for all-cause mortality \((n = 516\) participants) (6, 32, 33), 1 for total CVD \((n = 94\) participants) (20), 1 for CVD mortality \((n = 401\) participants) (21), and 2 for stroke (“silent” lacunar infarcts) \((n = 1378\) participants) (3, 22) (Figure 1).

Study characteristics

From the included studies, 2 were conducted in Australia (6, 33), 1 in the Netherlands (32), 1 in Italy (21), 2 in Japan (3, 22), and 1 in South Korea (34). Three cohorts were identified that reported all-cause mortality (6, 32, 33). The first study was a prospective cohort study of 179 semi-independent residents with a mean age of 83.2 y living in long-term health care facilities in Canberra, Australia, and followed over 4.7 y (6). The second study was a retrospective study of 302 consecutive patients, mean age of 78.7 y, who attended a falls clinic in the Netherlands and were followed for a mean of \(\sim 2\) y (32). The third was a small study of 35 patients older than 70 y who had been discharged from the intensive care unit 3 mo previously and were followed for a further 9 mo (33). One study was included for total CVD that followed 94 people, aged \(>70\) y, from 3 community centers in B city, South Korea, for 3 y (34). For CVD mortality, again only 1 study was included, and the cohort consisted of 401 patients, mean age 77.8 y, attending a cardiac clinic in Modena, Italy, and followed for a mean of over 4 y (51 mo) (21). Two
cross-sectional studies from Japan on stroke ("silent" lacunar infarcts) were included; 1 study was in 70 hospitalized patients, aged ≥60 y, with essential hypertension (22) and the other in 1308 older community residents with a mean age of 65.2 y (3) (Table 1).

**Risk of bias**

The quality of the cohort studies was assessed according to the NOS, and all studies were of high quality, receiving a score of 7 or higher (Supplemental Table 2). The JBI appraisal checklist for analytical cross-sectional studies was used to assess the quality of the included cross-sectional studies, and the overall appraisal was “Include” (Supplemental Table 3).

**Association between PPH all-cause mortality, total CVD, CVD mortality, and stroke**

Data from these 3 studies including 516 participants (6, 32, 33) demonstrated an association with increased risk of total mortality in those with PPH (RR: 1.48; 95% CI: 1.03, 2.14; \(P = 0.03\)) with minimal heterogeneity (\(I^2 = 8\%\); \(P = 0.34\)) (Figure 2).

Total CVD was only assessed in usable form in 1 study with 94 participants (34). The definition of CVD for this particular study was broad and included new-onset congestive heart failure, angina, and transient ischemic attacks in addition to MI and stroke. A positive association with PPH and CVD was reported with a very large risk ratio and confidence interval (RR: 11.18; 95% CI: 2.43, 51.41; \(P = 0.002\)). Two deaths were also recorded for MI and 2 from stroke, but their relation to PPH was not reported separately.

Similarly, only 1 study (\(n = 401\) participants) was included for cardiovascular mortality (21). The risk ratio for the association of PPH with all cardiovascular mortality was close to unity but significant due to narrow confidence intervals (RR: 1.18; 95% CI: 2.43, 51.41; \(P = 0.002\)).

The 2 cross-sectional studies determined the association between PPH and stroke ("silent" lacunar infarcts) assessed by MRI in 1378 participants (3, 22). Together, these studies demonstrated an association between PPH and stroke ("silent" lacunar infarcts) (RR: 1.69; 95% CI: 1.21, 2.36; \(P = 0.03\); \(I^2 = 0\%\)).

The association of PPH with the combination of all outcomes (\(n = 3289\) participants) was significant (RR: 1.52; 95% CI: 1.05, 2.18; \(P = 0.03\); \(I^2 = 77\%\)) (Figure 2).

**Subgroup analyses**

Subgroup analyses were undertaken to compare the associations of PPH by geography and culture (Japan and South Korea compared with Australia, the Netherlands, and Italy), by study type (cohort compared with cross-sectional studies), and age (mean cohort age above and below 70 y). The relative risks for all comparisons were similar and no interaction terms were significant (Supplemental Figures 1–3).

**Grading of the evidence**

The certainty of evidence was considered very low for all outcomes, but we believe it noteworthy that PPH was significantly associated with both the combined and each individual component outcome (Supplemental Table 4).

**Discussion**

These data indicate an association between PPH, cardiovascular outcomes, and all-cause mortality. However, the small sample size and high heterogeneity may lower the credibility and utility of the evidence in our meta-analysis. Nevertheless, each outcome lay to the right side of the unity line, and individually, they were significant. Interestingly, despite the apparently common occurrence of PPH, there were few data available on the nature of the foods or the macronutrient profiles of the meals that precipitate PPH. This disorder appears to have a higher prevalence in those with diabetes and in the institutionalized elderly that may be as high as 25–38% (4, 6, 7). Not only is it a potential cause of syncope, falls, and fractures, but our data suggest that PPH may also be significantly associated with CVD and total mortality.

Further studies are essential, but the studies associated with CVD and CVD mortality are also supported by a number of other reports on associations with PPH that were not included in this meta-analysis because the data provided were incomplete. One large study by Aronow and Ahn (4) in this area was not included in our meta-analysis because the data were not provided in the appropriate form. They assessed 499 older nursing home residents with a follow-up of 29 mo for falls, syncope, MI, stroke, and all-cause mortality. In this study, reductions in blood pressure of 17–23 mmHg were all significantly greater in those who had an event compared with the mean systolic blood pressure reductions of 12–15 mmHg in those who did not experience these conditions (4).

The MRI studies of the association with lacunar infarcts are of particular interest (3, 22) as these often asymptomatic events are associated with cognitive decline and are strongly associated with later symptomatic strokes (35). These infarcts occur deep in the white matter of the brain and also in the basal ganglia and pons and result from the occlusion of small perforating arteries. Over time, 30% of patients become dependent, and 25% have a further stroke within 5 y (36).

The mechanism by which PPH precipitates stroke and coronary events has not been clearly defined. Earlier studies indicated that, during exercise testing, hypotension accompanied the onset of angina in patients with coronary artery disease and in whom bypass surgery eliminated the fall in blood pressure, angina, and S-T depression (37). Concerns have been expressed over the effect of hypotension on symptomatic and silent ischemia in patients with ischemic heart disease associated with hypotensive drug therapy (38), particularly in patients with low diastolic blood pressure (39). Furthermore, in patients undergoing noncardiac surgery, intraoperative hypotension was seen to be a risk factor for perioperative MI (40). In relation to stroke, orthostatic hypotension in the 11,707 persons in the Atherosclerosis Risk in Communities cohort, followed over 7.9 y, was associated with an increased risk of stroke (HR: 2.0; 95%
### TABLE 1  Characteristics of included cohort and cross-sectional studies

| Study, year      | Country  | Design               | Participants                  | Number of events (cases/controls) | Age, mean ± SD, y | BMI, mean ± SD, kg/m² | Follow-up | Methods of outcome assessment | Outcomes           |
|------------------|----------|----------------------|-------------------------------|-----------------------------------|-------------------|------------------------|-----------|-------------------------------|--------------------|
| Kohara et al., 1999 (22) | Japan    | Cross-sectional      | 70 hospitalized essential hypertensive patients | 37 F, 33 M                     | 15/3              | 62.8 ± 8.1             | NA        | MRI report                     | Stroke ("silent" lacunar infarcts) |
| Fisher et al., 2005 (6) | Australia | Prospective cohort  | 179 ELD (semi-independent residents) | 144 F, 35 M                     | 11/5              | 69.2 ± 6.9             | 23.4 ± 3.8 | Not reported                   | All-cause mortality |
| Lagro et al., 2012 (32) | The Netherlands | Retrospective cohort | 302 ELD (consecutive patients visiting falls outpatient clinic) | 191 F, 111 M                   | 58/244             | 83.2 ± 7.0             | 26.2 ± 4.4 | Record linkage                  | All-cause mortality |
| Zanasi et al., 2012 (21) | Italy    | Prospective cohort  | 401 ELD (hypertensive)         | 214 F, 187 M                    | 34/333             | 77.8 ± 11              | 26.3 ± 3.6 | Record linkage and self-report | CVD mortality       |
| Tabara et al., 2014 (3) | Japan    | Cross-sectional      | 1308 ELD                      | 794 F, 514 M                    | 118/1072           | 65.2 ± 9.1             | 23.3 ± 3.1 | MRI report                     | Stroke              |
| Ali Abdelhamid et al., 2020 (33) | Australia | Prospective cohort  | 35 ELD (post-ICU discharge)    | 3/32 (at 9 mo)                 | 10/25               | 74 ± 4.5               | 28.7 ± 9.8 | Record linkage and self-report | All-cause mortality |
| Jang, 2020 (34) | South Korea | Prospective cohort  | 94 ELD                        | 79 F, 15 M                      | 47/47              | 73.1 ± 4.8             | 23.7 ± 2.5 | Record linkage and self-report | CVD                 |

1CVD, cardiovascular disease; ELD, elderly; ICU, intensive care unit; NA, not applicable; PPH, postprandial hypotension.
CI: 1.2, 3.2) (41). These data, although not related to PPH per se, support the hypothesis that repeated episodes of hypotension may have negative effects on the cardiovascular system, especially in those with preexisting CVD.

Both dietary and pharmacologic approaches have been shown to reduce the occurrence of PPH and give insights into the mechanisms of PPH. As pharmacologic treatment, glucagon-like peptide 1 agonists have been shown to reduce PPH by reducing the rate of gastric emptying and decreasing superior mesenteric artery blood flow, although the effect in delaying gastric emptying is reported to be transient (36). Similarly, as expected, dipeptidyl peptidase 4 inhibitors, by preventing incretin degradation, also reduce gastric emptying and therefore PPH (18). The somatostatin analogue octreotide reduces gastric emptying, decreases small intestinal peristalsis, and causes splanchnic vasoconstriction. This combination of actions has been shown to reduce PPH (19). Considerable research has been done on the drug acarbose, the α glycoside hydrolase inhibitor that reduces the rate of carbohydrate digestion and absorption (36). As expected, this change also has been shown to be effective in reducing PPH (42) and to reduce splanchnic blood flow in elderly inpatients diagnosed with PPH (43). As little as 50 mg acarbose taken with meals has been shown to reduce superior mesenteric artery blood flow, the postprandial fall in systolic blood pressure, and the rise in pulse rate (42).

Dietary measures that have been recommended to reduce PPH include eating smaller and more frequent meals, reducing meal carbohydrate content, and consuming more fluid with meals. These measures are aimed at reducing the osmotic activity of

![Forest plot of studies examining the association between postprandial hypotension, with all-cause mortality, total cardiovascular disease (CVD) risk, CVD mortality, and stroke (“silent” lacunar infarcts). Data are expressed as RR with 95% CI, using generic inverse-variance random-effects models. Interstudy heterogeneity was tested by using the Cochrane Q statistic (χ²) at a significance level of P < 0.10 and quantified by I² statistics.](image-url)
the gastric and small intestinal contents and thereby reducing the requirement for increased mesenteric blood flow and the resulting fall in systemic blood pressure (8, 9, 18).

It is of interest that rapidly digested, high glycemic index foods have also been associated with increased risk of stroke, total CVD, and total mortality in a large cohort study (44). The observation that PPH resulting from ingestion of rapidly absorbed carbohydrates is also associated with CVD and total mortality suggests a possible shared etiology and that dietary carbohydrates selected by those with PPH should also be low glycemic index.

The chief limitations of this analysis are the relatively few and small studies on all-cause mortality and cardiovascular outcomes, which, due to limited statistical power, weaken the validity of our study. The lack of studies may be due to the inconvenience of testing that involves preparing standard fresh breakfasts, establishing a stable baseline, and taking measurements at 15-min intervals over the following 2 h. We included 2 cross-sectional studies for stroke. Their results were consistent. Their elimination resulted in an overall loss of significance (RR: 1.47; 95% CI: 0.90, 2.41; \( P = 0.12 \)), although the risk ratio remains unchanged. There was also evidence of heterogeneity between study estimates. We did not downgrade the evidence for inconsistency as all the point estimates lay to the right side of the unity line. Furthermore, because both the overall and identified outcomes individually showed significant associations with PPH, we consider these associations to be noteworthy, acknowledging that there is an increased risk of type I error that results from analyzing multiple outcomes.

There are several strengths of this synthesis. It is based on a comprehensive systematic search of the available literature and included a GRADE assessment to assess the certainty of the evidence.

Finally, it is of interest that the elderly, those with diabetes, and those with increased CVD risk are the groups with the highest risk for PPH and also for adverse outcomes following coronavirus infection (45, 46). Would adequate treatment of PPH in these groups help to lessen the severity of the consequences of infection?

In conclusion, PPH is associated with higher cardiovascular outcomes and all-cause mortality. Confidence in the available evidence must be limited. More data are obviously required, but given the seriousness of the outcomes, we believe the evidence is sufficiently compelling to warrant more routine assessment of this condition and consideration of hygienic measures and, if necessary, drugs that are used commonly in the treatment of diabetes, as a potential means to reduce the ill effects of PPH (44).

The authors’ responsibilities were as follows—DJAJ: conceptualized the meta-analysis, designed the overall research plan, and is the study guarantor; SS-P: conducted the database search, analyzed the data, and revised the manuscript; KK, FL, MK, JW, MW, and KSChvaganesh: screened studies for inclusion, extracted the data, and revised the manuscript; DJAJ and JLS: drafted and revised the manuscript; MP, DP, AIG, KSirichaikul, and CWCK revised the manuscript; and all authors: reviewed and approved the final version of the manuscript.

Author disclosures: DJAJ has received research grants from Loblaw Companies Ltd., the Almond Board of California, Soy Nutrition Institute (SNI), and the Canadian Institutes of Health Research (CIHR). He has received in-kind supplies for trials as a research support from the Almond Board of California, Walnut Council of California, the Peanut Institute, Barilla, Unilever, Unico, Primo, Loblaw Companies, Quaker (PepsiCo), Pristine Gourmet, Bunge Limited, Kellogg Canada, and WhiteWave Foods. He has been on the speakers panel, served on the scientific advisory board, and/or received travel support and/or honoraria from Nutritional Fundamentals for Health (NFH)–Nutramedica, Saint Barnabas Medical Center, University of Chicago, 2020 China Glycemic Index International Conference, Atlantic Pain Conference, Academy of Life Long Learning, Loblaw Companies Ltd., Diet Quality Photo Navigation, Better Therapeutics (FareWell), Verywell, True Health Initiative, Heali AI Corp, Institute of Food Technologists, SNI, Herbalife Nutrition Institute, Herbalife International, Pacific Health Laboratories, NFH, the Soy Foods Association of North America, the Nutrition Foundation of Italy, the Toronto Knowledge Translation Group (St. Michael’s Hospital), the Canadian College of Naturopathic Medicine, The Hospital for Sick Children, the Canadian Nutrition Society, and the American Society of Nutrition (ASN). He is a member of the International Carbohydrate Quality Consortium (ICQC). He has received funds for dietary studies from Loblaw’s, which, during the course of his funding, acquired Shopper’s Drugmart, which is a pharmaceutical company that also sells supplements. His wife, Alexandra L Jenkins, is a director and partner of INQUIS Clinical Research for the Food Industry; his 2 daughters, Wendy Jenkins and Amy Jenkins, have published a vegetarian book that promotes the use of the low glycemic index plant foods advocated here, The Portfolio Diet for Cardiovascular Risk Reduction (Academic Press/Elsevier 2020); and his sister, Caroline Brydson, received funding through a grant from the St. Michael’s Hospital Foundation to develop a cookbook for one of his studies. He is also a vegan. (Please see full conflict of interest declared in J Am Coll Cardiol 2018;71(22):2570–2584 prior to 2018). JLS has received research support from the Canadian Foundation for Innovation, Ontario Research Fund, Province of Ontario Ministry of Research and Innovation and Science, CIHR, Diabetes Canada, PSI Foundation, Ban ting and Best Diabetes Centre, ASN, INC International Nut and Dried Fruit Council Foundation, National Honey Board (the USDA honey “Checkoff” program), Institute for the Advancement of Food and Nutrition Sciences (IAFNS; formerly ILSI North America), Pulse Canada, Quaker Oats Center of Excellence, The United Soybean Board (the USDA soy “Checkoff” program), The Tate and Lyle Nutritional Research Fund at the University of Toronto, The Glycemic Control and Cardiovascular Disease in Type 2 Diabetes Fund at the University of Toronto (a fund established by the Alberta Pulse Growers), The Plant Protein Fund at the University of Toronto (a fund that has received contributions from International Flavors & Fragrances Inc. (IFF), and The Nutrition Triallists Fund at the University of Toronto (a fund established by an inaugural donation from the Calorie Control Council). He has received food donations to support randomized controlled trials from the Almond Board of California, California Walnut Commission, Peanut Institute, Barilla, Unilever/Uptfield, Unico/Primo, Loblaw Companies, Quaker, Kellogg Canada, WhiteWedge Foods/Torone, Nature’s, and Dairy Farmers of Canada. He has received travel support, speaker fees, and/or honoraria from ASN, Danone, Dairy Farmers of Canada, FoodMinds LLC, International Sweeteners Association, Nestlé, Pulse Canada, Abbott, General Mills, Comité Européen des Fabricants de Sucre, Nutrition Communications, International Food Information Council, Calorie Control Council, and International Glutamate Technical Committee. He has or has had ad hoc consulting arrangements with Perkins Coie LLP, Tate & Lyle, and Inquis Clinical Research. He is a member of the European Fruit Juice Association Scientific Expert Panel and former member of the SNI Scientific Advisory Committee. He is on the Clinical Practice Guidelines Expert Committees of Diabetes Canada, European Association for the Study of Diabetes (EASD), Canadian Cardiovascular Society, and Obesity Canada/Canadian Association of Bariatric Physicians and Surgeons. He serves or has served as an unpaid scientific advisor for the Food, Nutrition, and Safety Program and the Technical Committee on Carbohydrates of IAFNS (formerly ILSI North America). He is a member of the ICQC, executive board member of the Diabetes and Nutrition Study Group (DNSG) of the EASD, and director of the Tokyo 3D Knowledge Synthesis and Clinical Trials foundation. His spouse is an employee of AB InBev (please see full conflict of interest declared in Prog Cardiovasc Dis 2018;61(1):43–53 prior to 2018). CWCK has received grants or research support from the Advanced Food Materials Network, Agriculture and Agri-Foods Canada, Almond Board of California,
References

1. Fukushima T, Asahina M, Fujinuma Y, Yamanaka Y, Katagiri A, Mori M, et al. Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy. J Neurol 2013;260(2):475–83.

2. Hashizume M, Kimami S, Sakurai K, Izawa KP, Shiotani H. Postprandial blood pressure decrease in patients with type 2 diabetes and mild or severe cardiac autonomic dysfunction. Int J Environ Res Public Health 2019;16(5):812.

3. Tabara Y, Okada Y, Uetani E, Nagai T, Igase M, Kido T, et al. Postprandial hypotension as a risk marker for asymptomatic lacunar infarction. J Hypertens 2014;32(5):1084–90; discussion 90.

4. Aronow WS, Ahn C. Association of postprandial hypotension with incidence of falls, syncope, coronary events, stroke, and total mortality at 29-month follow-up in 499 older nursing home residents. J Am Geriatr Soc 1997;45(9):1051–3.

5. Trahair LG, Horowitz M, Jones KL. Postprandial hypotension: a systematic review. J Am Med Dir Assoc 2014;15(6):394–409.

6. Fisher AA, Davis MW, Srikusalanukul W, Budge MM. Postprandial hypotension predicts all-cause mortality in older, low-level care residents. J Am Geriatr Soc 2005;53(8):1313–20.

7. Le Couteur DG, Fisher AA, Davis MW, McLean AJ. Postprandial systolic blood pressure responses of older people in residential care: association with risk of falling. Gerontology 2003;49(4):260–4.

8. Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med 1995;122(4):286–95.

9. Kooner JS, Raimbach S, Watson L, Bannister R, Peart S, Mathias CJ. Relationship between splanchnic vasodilation and postprandial hypotension in patients with primary autonomic failure. J Hypertens 1989;7(6):S40–41.

10. Gentilcore D, Hausken T, Meyer JH, Chapman IM, Horowitz M, Jones KL. Effects of intraduodenal glucose, fat, and protein on blood pressure, heart rate, and splanchnic blood flow in healthy older subjects. Am J Clin Nutr 2008;87(1):156–61.

11. Pham H, Trahair L, Phillips L, Rayner C, Horowitz M, Jones K. A randomized, crossover study of the acute effects of acarbose and gastric distension, alone and combined, on postprandial blood pressure in healthy older adults. BMC Geriatr 2019;19(1):241.

12. Mathias CJ. Postprandial hypotension: pathophysiological mechanisms and clinical implications in different disorders. Hypertension 1991;18(5):694–704.

13. Vanis L, Gentilcore D, Hausken T, Pillichiewicz AN, Lange K, Rayner CK, et al. Effects of gastric distension on blood pressure and superior mesenteric artery blood flow responses to intraduodenal glucose in healthy older subjects. Am J Physiol Regul Integr Comp Physiol 2010;299(3):R960–7.

14. Feldman RD, Bierbrier GS. Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lancet 1993;342(8873):707–9.

15. Lipsitz LA, Ryan SM, Parker JA, Freeman R, Wei JY, Goldberger AL. Hemodynamic and autonomic nervous system responses to mixed meal ingestion in healthy young and old subjects and dysautonomic patients with postprandial hypotension. Circulation 1993;87(2):391–400.

16. Gentilcore D, Bryant B, Wishart JM, Morris HA, Horowitz M, Jones KL. Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly. Am J Med 2005;118(11):1289.e5.

17. Jones KL, MacIntosh C, Su YC, Wells F, Chapman JM, Tonkin A, et al. Guar gum reduces postprandial hypotension in older people. J Am Geriatr Soc 2001;49(2):162–7.

18. Agarwal A, Inayat E, Liang F. The glycinemic index, postprandial hypotension and cardiovascular disease. Int J Heart Vasc Syst 2021;2(1):9–13.

19. Borg MJ, Xie C, Rayner CK, Horowitz M, Jones KL, Wu T. Potential for gut peptide-based therapy in postprandial hypotension. Nutrients 2021;13(8):2826.

20. Jang A. Postprandial hypotension as a risk factor for the development of new cardiovascular disease: a prospective cohort study with 36 month follow-up in community-dwelling elderly people. J Clin Med 2020;9(2):345.

21. Zanasi A, Tincani E, Evandi V, Giovanardi P, Bertolotti M, Riolli G. Meal-induced blood pressure variation and cardiovascular mortality in ambulatory hypertensive elderly patients: preliminary results. J Hypertens 2012;30(11):2125–32.

22. Kohara K, Jiang Y, Igase M, Takata Y, Fukuoka T, Okura T, et al. Postprandial hypotension is associated with asymptomatic cerebrovascular damage in essential hypertensive patients. Hypertension 1999;33(1):565–8.

23. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane handbook for systematic reviews of interventions [Internet]. Version 6.3. (Oxford (UK): Cochrane Collaboration; 2011 [cited 2021 Sep 2]. Available from: www.training.cochrane.org/handbo...
34. Jang A. Postprandial hypotension as a risk factor for the development of new cardiovascular disease: a prospective cohort study with 36 month follow-up in community-dwelling elderly people. J Clin Med 2020; 9(2):345.
35. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 1997;28(10):1932–9.
36. Samuelsson M, Söderfeldt B, Olsson GB. Functional outcome in patients with lacunar infarction. Stroke 1996; 27(5):842–6.
37. Thomson PD, Kelemen MH. Hypotension accompanying the onset of exertional angina: a sign of severe compromise of left ventricular blood supply. Circulation 1975;52(1):28–32.
38. Owens P, O’Brien E. Hypotension in patients with coronary disease: can profound hypotensive events cause myocardial ischaemic events? Heart 1999;82(4):477–81.
39. Peri-Okonny PA, Patel KK, Jones PG, Breeding T, Gosch KL, Spertus JA, et al. Low diastolic blood pressure is associated with angina in patients with chronic coronary artery disease. J Am Coll Cardiol 2018;72(11):1227–32.
40. Hallqvist L, Granath F, Fored M, Bell M. Intraoperative hypotension and myocardial infarction development among high-risk patients undergoing noncardiac surgery: a nested case-control study. Anesth Analg 2021;133(1):6–15.
41. Benvenuto LJ, Krakoff LR. Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease. Am J Hypertens 2011;24(2):135–44.
42. Wang B, Zhao J, Zhan Q, Wang R, Liu B, Zhou Y, et al. Acarbose for postprandial hypotension with glucose metabolism disorders: a systematic review and meta-analysis. Front Cardiovasc Med 2021;8:663635.
43. Qiao W, Li J, Li Y, Qian D, Chen L, Wei X, et al. Acarbose, the α-glucosidase inhibitor, attenuates the blood pressure and splanchnic blood flow responses to meal in elderly patients with postprandial hypotension concomitant with abnormal glucose metabolism. Blood Press Monit 2016;21(1):38–42.
44. Jenkins DJA, Dehghan M, Mente A, Bangdiwala SI, Rangarajan S, Srichaikul K, et al. Glycemic index, glycemic load, and cardiovascular disease and mortality. N Engl J Med 2021;384(14):1312–22.
45. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584(7821):430–6.
46. Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis. Int J Infect Dis 2020;99:47–56.